<code id='4519518C07'></code><style id='4519518C07'></style>
    • <acronym id='4519518C07'></acronym>
      <center id='4519518C07'><center id='4519518C07'><tfoot id='4519518C07'></tfoot></center><abbr id='4519518C07'><dir id='4519518C07'><tfoot id='4519518C07'></tfoot><noframes id='4519518C07'>

    • <optgroup id='4519518C07'><strike id='4519518C07'><sup id='4519518C07'></sup></strike><code id='4519518C07'></code></optgroup>
        1. <b id='4519518C07'><label id='4519518C07'><select id='4519518C07'><dt id='4519518C07'><span id='4519518C07'></span></dt></select></label></b><u id='4519518C07'></u>
          <i id='4519518C07'><strike id='4519518C07'><tt id='4519518C07'><pre id='4519518C07'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:knowledge    Page View:38
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In